Journal
GLIA
Volume 71, Issue 4, Pages 1099-1119Publisher
WILEY
DOI: 10.1002/glia.24328
Keywords
astrocytes; GFAP; HDAC5; painful diabetic neuropathy; spinal cord; STAT3
Categories
Ask authors/readers for more resources
Diabetes patients with painful diabetic neuropathy (PDN) exhibit spinal atrophy and degeneration of astrocytes, leading to pain hypersensitivity. The impaired acetylation of STAT3 in astrocytes and aberrant activation of HDAC5 promote astrocyte deficiency, contributing to the development of PDN in a rat model of type 1 diabetes (T1D). Restoring STAT3 signaling or inhibiting HDAC5 rescues astrocyte deficiency and attenuates PDN, highlighting the therapeutic potential for targeting the HDAC5-STAT3 axis in diabetic spinal cord pathogenesis.
Diabetes patients with painful diabetic neuropathy (PDN) show severe spinal atrophy, suggesting pathological changes of the spinal cord contributes to central sensitization. However, the cellular changes and underlying molecular mechanisms within the diabetic spinal cord are less clear. By using a rat model of type 1 diabetes (T1D), we noted an extensive and irreversible spinal astrocyte degeneration at an early stage of T1D, which is highly associated with the chronification of PDN. Molecularly, acetylation of astrocytic signal transducer and activator of transcription-3 (STAT3) that is essential for maintaining the homeostatic astrocytes population was significantly impaired in the T1D model, resulting in a dramatic loss of spinal astrocytes and consequently promoting pain hypersensitivity. Mechanistically, class IIa histone deacetylase, HDAC5 were aberrantly activated in spinal astrocytes of diabetic rats, which promoted STAT3 deacetylation by direct protein-protein interactions, leading to the PDN phenotypes. Restoration of STAT3 signaling or inhibition of HDAC5 rescued astrocyte deficiency and attenuated PDN in the T1D model. Our work identifies the inhibitory axis of HDAC5-STAT3 induced astrocyte deficiency as a key mechanism underlying the pathogenesis of the diabetic spinal cord that paves the way for potential therapy development for PDN.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available